- NewsCategory：
- All Company news Industry news
common105One result
-
1031
Gotham Therapeutics ↓↕Establishes Advanced Oncology Profil✔©↔ing Cascade with ProQinase to Progress it≈←≥s Portfolio of Epitranscriptomic Drug ←∑ Candidates
Gotham Therapeutics Est>♦ablishes Advanced OnΩ§©cology Profiling Cascade with ProQinase to P&"★rogress its Portfolio of Epitranscriptomic Drug≤ σ CandidatesWEDNESDAY, OCTOB≥π©↔ER 30, 2019Gotham Therapeuti☆εσ∞cs, a biotechnology company developi★ ng a novel drug class targeting RNA-m♠αγodifying proteins, a'∑×αnd ProQinase, an early stage drug-discΩ£overy company, recently acquired by Malver<∏$♣n/PA-based Reaction Biology Cα♠£orp., today announced that ↑δthey have established an array of advanced bioche✔σ♠✔mical and cellular assays to charact≤♠erize epitranscriptoφ mic-directed compounds.“Estab♥ πlishing tailored target engagemen€★t, cell biology, phenotypic, and in-vi∑ εvo assays to evaluate compound↑♦♠↕s originating from our three most advance>₽Ωd epitranscriptomic programs in"₹♣ parallel is a crucial next step to develop ou→γr broad pipeline towa ÷rds the clinic,” said Dr. Gerhard Mülle ×₹↑r, Chief Scientific Officer of Gotham Theraδ<¶peutics. “By pursuing th₩¥☆e full range of the reader-writer-eraser co'×≤ntinuum, we are able to focus on targets↔δ with the most compellin÷∏αg links to disease and advance those prog"™rams in tandem.”“Com> ∑bining our high proficiency in providing customiz'♠ed solutions as early♦ ₩£ stage drug-discovery servic™<es, including tailor-made bioch∑emical and cell-based assays, with Gotha↔ βm’s expertise in epitranscrip☆±tomics, we were able to estabβγ≈lish in a very short time a set o±γ®☆f customized enzymatic and cellular assays ®₹ for compounds addressing three differ↕Ωent mRNA-modifying targets,” said¥£ Dr. Sebastian Dempe, Chief Executive Officer o&£↑→f ProQinase. “We look forward to supporting ♠'<Gotham as the company advances its p↑∞₩rograms into lead optimization and to contin¶ε®δued work with the Gotham team assisting the compa₽♠ny to advance its broad pipeline in a time-efγ±✔<fective manner.”In addition to ∏↕♣establishing a tailor-≈©made profiling cascade fo§©γλr compounds from its three most advanced program<←s, Gotham has also made ¶πprogress in strengthening its drug discovery ↕λ®φengine and developing its candidate& base. Gotham previously c✔×ompleted the gene-to-lead phase for its dr↔↔★λug discovery project targeting the METTL3/ME↕¶TTL14 complex and established a robust discove×₩ry process as a platform foλ®±✔r future projects. The ₽βcompany has also generated a library of high-qual×♠'ity compounds tailor-made for accele☆εφrated hit generation and hit≠★¥₹-to-lead expansion against large parts of the epi≥★>transcriptomic target space. Th♠§is library includes a collection→& of over 2,000 analogues cove€♠↕ring over 80 distinct chemotypes tha✘&™t will be used to further accelerate ←™₩Gotham’s drug discovery effortsε"★£ as it expands its pipeline.The original link:π♣♣$https://www.pharmafo§×≤cusasia.com/news/gotham-therapeutics-es≥ λtablishes-advanced-oncology-p©♣δrofiling-cascade-with-proqinase-tγ←o-progress-its-portf"♦§↓olio-of-epitranscriptomic-drug-candi÷✔dates2019 Asia-pacific pharma IP Leader Summi♦<πt: http://en.zenseegroup.com/p/510934/☆Ω ¶will be held in Beijing&•→™nbsp; on November 14-15, and wi∞★"₩ll attract more than 500 industry & experts from domestic and foreign pharmaπceutical companies, biotechnol≥ogy companies, governments, associaα₽✘tions, law firms, intellectual ☆✔property agents and other companies קσ<to attend.Official registration and consu•₹ ★ltation channels:Contact：AnnPhone: ♦β021-65650305Email：Marketing@λεε₹zenseegroup.comhttp://en.zens♥Ωeegroup.com/p/510934 -
1030
Gilead and Glympse Bio π$∑πAnnounce Strategic Collaboration for UseφΩσ of Biomarker Technology in NASH Cli>λ↕>nical Development
Gilead and Glympse Bi♠&o Announce Strategic Collab ♦oration for Use of Biomarker §↕Technology in NASH Clinica♦δl DevelopmentTUESDAY, OCTOBE&≈≈R 29, 2019Gilead Sciences Inc. a™ ✘nd Glympse Bio, Inc., today☆㣩 announced that the companies have e♣" ★ntered into a strategic col↕δlaboration in nonalcoholic ste¥β€atohepatitis (NASH) clinical deve±±lopment. Glympse Bio’s proprietary synthetic bio♥✔↓markers – bioengineered to identify st÷δage and progression of disease as we">≈ll as early detection of treatment responφ↕se – will be used to determine cli₩★±≠nical trial participaε≤→nts’ stage of disease atβ©₽Ω initial screening and to determine responses to ≠εε÷study treatment in G§≈ilead’s NASH clinical program.“We are exciteΩ≥d about the opportunity to partner with Glymp♠εse Bio to help inform oγ∑δur NASH development program,®←₹” said Mani Subramanian, MD, γ¥♠↕PhD Senior Vice Presi≥↓dent, Liver Diseases, Gilead Sciences. •"¥☆“By utilizing this innovative tec" ♠σhnology, we hope to better cha↔¶←racterize this complex disease an£©d improve our understandingα∏ε of how our compounds impact disease progression®σ .”Glympse Bio’s proprietary technol<β¶'ogy, Glympse Inside™, combines syε✘nthetic biomarkers with®±α machine learning approaches to identify the s≈₽♠₩tage and monitor progression of important∏↕, complex diseases such as cancer, fibrosis, ★©inflammation, and infections, in real time.“☆←±We are very excited about ✘δpartnering with Gilead, a leader in drug de<$velopment, to help drive earlier and ♥≈§more favorable outcomes ←for patients,” said Caroline J Loew, P₩↕←↑resident and CEO, Glympse Bio. “Gilead’s commiφπtment to developing innovative med•¥×λicines in areas of high unme↓×t medical need aligns with o≤¥≈ur mission of transforming disease de¥™tection and measuring treatment≠ε↓♣ response, all with the goal of helping improve≠<™ the lives of patients.”φ★ε±information source:pharma foΩ∏§•cus AsiaThe original link:http♠∑ ¶s:https:https://www.pharmafocusasiaδ¥.com/news/gilead-and-glympse&§-bio-announce-strategic-collaborati∞λon-for-use-of-biomarker-technology-in-n↔∑ash-clinical-development2019 Asia-pacific pharm★'₽a IP Leader Summit:h©↑©αttp://en.zenseegroup.com/p/510934/&nbε₽£÷sp;will be held in Beijing≈→ on November 14-15, and α£ ¶will attract more than 500 industr≈π€y experts from domestic and foreign pharm∞®aceutical companies, biotec♥&hnology companies, governments, asso$©×ciations, law firms, intellectual property agen∑αts and other companies to ∞§attend.Official registration anπ $™d consultation channels:Contact：AnnPhone: 021-6σ≈'5650305Email：Marketing@zenseegro☆δ←up.comhttp://en.zenseegroup.com/p/5€ 10934 -
1029
HistoIndex Announces Global Partnerships To E¶βxpand AI-Based Digital Pathology σPlatform
HistoIndex Announces Global Partnerships To Ex≤✔pand AI-Based Digital Pathology PlatformMOND©α₽£AY, OCTOBER 28, 2019Histo♠✘εIndex announces the expansion of its A§δI-based digital pathology p latform towards large-scale NASH pr≠☆δeclinical programs for pharmaceutical and biot±ε∏ech companies to ach&"¥≠ieve quantifiable and reproducible data on '¥ therapeutic responses in N♣'ASH animal models, and to aid CR↕Os as well as research agencies in validati₩ ng new models mimicking th÷←e NASH disease.Published preclinical stα♣udies have demonstrated the use of HistoInd ¶↑∞ex's fully quantifiabl∑""♥e Second Harmonic Generσ®'÷ation (SHG) technology as a¥₩ highly accurate stain-free method that can mo ♥nitor the efficacy of various therapeutic age£γnts, by quantifying more than 450 NASH-♥∞↕§associated parameters in fibros∑'is, inflammation, ballooning and steatosis. ☆→ ₹The information of the¶←βse NASH-associated parameters gathe≤★×red from the entire liver tissue, p≠ λ↓rovides comprehensive insights on the mecha§✘↔nism of action of the therapeutic ag≈♣∞ent. As a drug discovery tool, HistoI§♦'ndex's SHG-enabled digital pathology platform wilΩ <↔l allow pharmaceutical and biotech companies ↑ ≤to select promising lead cΩ₹andidates for further opti£★☆mization and make informed deciΩ↓$®sions in the management of their NASH drug de♦ εvelopment pipeline.In add≤γ↔ition to ongoing NASH clinical trials, HistoInd$≤←ex is currently involv→ed in multiple preclinical stu≥Ωσdies, most of which are conducted by major★ε pharmaceutical and biotech companies, medicα&®al universities, CROs and r∑<←©esearch agencies. Notably, HistoIndex has €∑♣σrecently entered into a>≥ collaboration with the A*STAR's Genome Insti♣•'↔tute of Singapore (GIS) to validate→ their in vivo and i♣©αn vitro NASH models based on Asian-c↔¶₩±entric clinical data. Says Professor Patrick Tan£✔♠π, Executive Director of the GenΩome Institute of Singapore∞'↓ (GIS), "At GIS, we conduct our preclinical s×γφtudies on fatty liver involvingε αδ data from animal models based on p>"≈λatient-derived transcriptomic data. This h®→₩<as a high translation• ₽∑al potential as it h ☆elps us to pinpoint newσ₽>∑ therapeutic targets and thei∏ε€r validation. Therefore, uδ¶sing a fully quantitative, reliabl→'↑§e and objective pathological eπβ✔valuation such as HistoIndex's AI-b×∏÷♣ased digital pathology p£ε♥'latform is essential to the succeΩλss of our efforts in therapeutic t≤δ$arget discovery."HistoIndex is also a part↕♠♠λner with globally-renowned CRO, WuXi Apptec£←♠, in advancing their NASH preclinical pro≈↓☆αgrams with advanced R&D and smart imagi×∞γng analysis capabilities. Published study data ↓≤•₹will be available for discussions during neε•tworking opportunities throughout AASLD↑★'s The Liver Meeting® ✔Ωσin November 2019. "We are very e ↔εxcited to extend our AI-b≥ε€ased SHG platform to preclinΩ<♣ ical studies to help companies with drug discover↓±¶y programs select promising le$♣δad candidates for further optimization×✘₹ and subsequent clinical dev÷♦§elopment," says Dr Poon Thong Yuen≥ ₹, Chief Executive Officer of His♥Ω®₩toIndex. "Our SHG image analysis platform has επalready been used to analyze the <efficacy of a series of promising ≥$drug candidates for NASH withi↓☆n various animal models §₹×commonly-used by the industry, and we ε☆∏♠believe these preclinical partners∏→ ★hips will help drive the adoption "↕Ω<of our platform significan€₽tly."information source:pharma focus AsiaT← he original link:https:https://www.pharm©¥₹≈afocusasia.com/news/histoindex-announces-global-β ✘&partnerships-to-expand-ai-based-digit↓×✔al-pathology-platformλ®2019 Asia-pacific ph"arma IP Leader Summit:€>✔ http://en.zenseegroup.com/p/510934/will be∞Ω"σ held in Beijing&n↕σbsp; on Noveπ≥mber 14-15, and will attract mor ₹®∏e than 500 industry experts from domes≠σ≤♣tic and foreign pharmaceutical co↑φmpanies, biotechnology companies, governm↑>ents, associations, law firms, i ∑✔ntellectual property ≈ agents and other companies to attend.Official ∑♦registration and consultation channels$£'↔:Contact：AnnPhone: 021-6565•♦Ωλ0305Email：Marketing@zenseegroup.co×π©Ωmhttp://en.zenseegroup.com/p/510934σ∞↓ -
1028
AVROBIO Receives Orphan-Drug Designation fro₹∑σm the U.S. FDA for AVR‑RD‑02 for×≈¥ the Treatment of Gaucher Disease
AVROBIO Receives Orp&®han-Drug Designation from the U.S♦£. FDA for AVR‑RD‑02 for the Treaα★tment of Gaucher DiseaseFRIDAY, ' →OCTOBER 25, 2019AVROBI × O, Inc., today announced that the U.S. Food andπ> Drug Administration (FDA) has granted orphan-dru≈©↔ g designation for the Company’s investi>♣gational gene therapy, AVR-RD-02,∞ for the treatment of Gaucher diseas™e. AVR-RD-02 consists ≥πσof the patient’s own hemato₽π&♠poietic stem cells, ★± ≥genetically modified to express ≤§←₽glucocerebrosidase (GCase), the enzym ε♦e that is deficient in Gaucher disease. The Comp₹★any is actively recruiting in Cana™<≈∑da for its Phase 1/2 clinical tria>σl of AVR-RD-02, which seeks to evalu↑ ate the safety and efficacy of t★₽♦he therapy in patients with T<Ωype 1 Gaucher disease.“ ←Under the existing standard of care, ₽≠patients with Gaucher disease are bound t←↓£o a lifelong infusion s$•©chedule of enzyme replacement therap≠♣ies, and still experience painα±∏ful and progressive symptoms such as debilit≈÷↕'ating musculoskeletal pain and fa™tigue,” said Birgitte>↔ Volck, MD, PhD, President of ★₽Research and Development at AVROBIO. “Orphan-dru£Ω₽g designation recognizes the unmet need of popula↔≠'tions with rare diseases like ∑β♦Gaucher where AVROBIO strives t¶σ£←o transform lives by addressing the ♣♦♣÷underlying cause of the disease wβ•ith a single dose of gene therapy.”OrphanΩ&$±-drug designation is gr↓÷$"anted by the FDA to drugs an™©>d biologics which are intended←✘ for the safe and effective trea≤>tment, diagnosis or prevention of rare ★↑↕βdiseases or conditions that affect fewer ♠∏than 200,000 people in the United S♦λ<tates. Orphan-drug designation provide≈φβ≥s certain incentives, which may include ™♣tax credits towards the cost of clinical tΩ'φrials and prescription drug use♠βΩr fee waivers.inform↕>↔★ation source:pharma ∑↔✘focus AsiaThe original link:https:https:δγ¶//www.pharmafocusasia.com/news/avrobi o-receives-orphan-drβ×♠ug-designation-from-the-✔✔us-fda-for-avrrd02-f®®↕©or-the-treatment-of-gaucher-disease2019 Asia-∑β↕pacific pharma IP Leader Summ↑ "βit: http://en.zenseegroup.co$≈$¶m/p/510934/will be held in Bei£ σjing on November 14-σ&π15, and will attract more than≤₩ 500 industry experts from domestic and foreig™★n pharmaceutical companies, biotechnolog₩©÷y companies, governments, as¥sociations, law firms, intellectσual property agents and other companies to attend§ .Official registration and consultation channels ♥Ω♠:Contact：AnnPhone: 021-65650305Email：Marke∞ <ting@zenseegroup.comhttp©→×://en.zenseegroup.com/p/510934 -
1026
AZTherapies Strengthens Neuroinflammation-T∞∞±☆argeted Pipeline Throughα♠α♦ Acquisition of Smith Therape₹≠✘utics
FRIDAY, OCTOBER 25, 2019÷ ★AZTherapies, Inc., a b™π♣iopharmaceutical company developin↕α✘€g therapeutics to extend↓"™ brain health, today announced the acquisiti <♦on of Smith Therapeuβ≈tics, a private biopharmaceutical company with $a shared goal of targeting neuεβα♣roinflammation to tr≤γ♣eat neurodegenerative disease. Smith Therapeφ♦δutics’ Founder and Chief Execut€λive Officer Philip Ashton-Ric"'¥kardt, Ph.D., has joined the senior£λ♣ leadership team at AZT< herapies as Senior Vice President o>γf Immunology. Financial te✘≤¶πrms of the acquisition we∏←¶↓re not disclosed.Smith Therapeutics’ p"β'roprietary research platε✔form focuses on the use of modified T cells<¥§ to restore a healthy balan§€ce of inflammatory and regulatory c$§ells in the brain. To date, Sm✔♠↕ith has successfully engineered £≥immunosuppressive T regulato&π←↑ry (Treg) cells with Chimeriλ≥§c Antigen Receptors (CARs) targeting brain≈↓ glial cells. Previous research has demon ∑εstrated the ability of Tregs to dampen×♥ microglial activity and reduce neuroinfl<←≈>ammation in models ofε♦ neurodegeneration, suggesting their λ₩→≈potential utility in the ✘δtreatment of diseases including ←£♣✘Progressive Supranuclear Palsy (PSP), Alzhei εmer’s disease, Parkinson’s disease, γ≥δ₹Huntington’s disease, Amy∑₽βotrophic Lateral Sclerosis (ALS), and₽Ω others.“This acquisition represents a meaningfu'∏'←l step forward for us as we con↕∞tinue to strengthen ↓↓←our leadership position in >&÷✘the development of therapies targeting neuroinfl↓ ammation to stop or slow the ↕≠>progression of neurodegenerative diseases,” •≈♦said David R. Elmaleh, Ph.D., Founder, CEO, and ↔§•¶Chairman of AZTherapies. “We are exc♥βited to be working wi♦♣•th Philip as we add this cutting-edge technolog ♣♥y to our portfolio o±¥ε'f innovative programs. An esteemed immun↓β∑¶ologist and inventor of ↔≤™the technology, Philip brings unparalleled expe€✘rtise to the company and we look forward to advλ≥ancing this CAR-Treg program further into™ IND-enabling studies and ≥♥into clinical development a$£s rapidly as possible.✔₩”Dr. Ashton-Rickardt commented on the a®±≤cquisition and his appoi∞♥₹≥ntment: “Our shared rationale of♠→↕ targeting neuroinflammation as σ∞the root cause of neurodegenerative diseas÷≈&εe makes this acquisition a gr ±↑eat strategic fit for us. Witπ♣γγh AZTherapies’ expertise in drug development ¥≥δand clinical trial executi≤₹γφon, we believe that together, we are w↓$→ell positioned to advance£↕∑∞ our CAR-Treg technology ∏•βand fundamentally change neurodegenerativ₩>e disease progression.”Prior ♣γ↔to launching Smith The∏&rapeutics in 2017, Dr. Ashton-Rickardt was φε♦Chair in Immunology at Imperial Coll&← ege London, Visiting Professor,♦¥ Brigham and Women’s Hospiσ<tal, Harvard Medical School, and"→♥↔ Associate Professor in the Depart£>ment of Pathology at t∑"he University of Chicago. His work has been recog&≥nized by his peers through ™ the award of tenure from The University of Cσ♦hicago and by his fellow citiz×≠ens as a recipient of the Early Career Award ≤×for Scientists and Engineers froπ☆✘★m President Bill Clinton. He ≠±÷πhas published more than 65 peer-reviewed pa₹≠♥pers in more than 30 aca✘₩demic journals (including Cell, © Science, Immunity, and N±₽ γature Immunology), has ser←∏ved as an editor for several a←$cademic journals, and h₹♥πas been a member of π☆grant review boards globally. Dr. Ashton-Rickard↕♦↑t received a B.Sc. inδβαβ Biochemistry from th₽αe University of London, King’s College with♥> honors, a Ph.D. in MoleculaΩ✘♦r Biology from the Univ•ersity of Edinburgh, and c"≈×↔ompleted post-doctora₩∑l work at the University of Edinburgh÷✘∏ and the MassachusettsΩ® Institute of Technology in "σMolecular Biology and Molecular Immunology, re¶σ®↓spectively.information source:pharma focus∑×≈ε AsiaThe original link:https:https://www.pharmafo♣←↓cusasia.com/news/azth←₩×erapies-strengthens-neuroinflammation-targetσ♦ed-pipeline-through-acquisit★β♣✘ion-of-smith-therapeutics2ε≤ 019 Asia-pacific pharma↑←<& IP Leader Summit: http://en.ze'→✘≈nseegroup.com/p/510934/will be held in✔÷± Beijing on ↕∞↔November 14-15, and will attract more t↔βhan 500 industry experts from domestεε ©ic and foreign pharmaceutical co↑♣λ±mpanies, biotechnology companies, government÷δs, associations, law firms, in₽ tellectual property agλ ☆ents and other companies to attend.Official σ'♦≥registration and consultation Ω★channels:Contact：AnnPhone: 0α₽•∑21-65650305Email：Marketing@↑&>zenseegroup.comhttp://en.zenseegroup.c∞$om/p/510934
Contact Us
Zensee_Daystar online
© 2011-2016